In plain words
AbbVie sold $17.4 billion of medicines in the three months to September, 10.3% more than a year earlier. Two immune-disease drugs, Skyrizi and Rinvoq, brought in $8.5 billion of that, almost half, and grew 23% together. They added about $1.6 billion of sales, close to the company's entire $1.6 billion increase. Humira, the blockbuster they are replacing, fell 31% to $683 million. Adjusted earnings per share doubled to $3.82, but most of that jump comes from a $2.7 billion charge for research deals that hit last year's quarter. AbbVie raised its full-year profit outlook and its dividend.
The finding
AbbVie has finished replacing Humira, and its growth now rides on two drugs. Skyrizi and Rinvoq made up 49% of revenue and about 98% of the year-on-year sales increase (AB Desk calc). Neuroscience is the second engine, up 19.4% to $3.4 billion. Oncology was flat and aesthetics shrank. The doubled EPS headline overstates the year: strip out acquired research charges from both quarters and adjusted EPS rose 17%, from $3.36 to $3.93 (AB Desk calc). That is still strong, and AbbVie backed it by lifting 2026 adjusted EPS guidance to $13.95–13.99 and raising the quarterly dividend 5.2%.
Market reaction: ABBV traded at $294.89, up 1.41% from its $290.79 close (CNBC, close Oct 30).
For educational purposes only; not investment advice.
The publisher may hold positions in some of the companies described and does not trade them from 3 trading days before to 3 trading days after publication.